triazolam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diazepam derivatives | 2729 | 28911-01-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | mg | O |
| 0.20 | mg | SL |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.05 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.02 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 44 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.58 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.10 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.70 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 15, 1982 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sopor | 622.69 | 14.97 | 202 | 9221 | 20720 | 56261924 |
| Drug abuse | 458.44 | 14.97 | 224 | 9199 | 67386 | 56215258 |
| Intentional self-injury | 203.15 | 14.97 | 94 | 9329 | 24898 | 56257746 |
| Overdose | 197.74 | 14.97 | 154 | 9269 | 105676 | 56176968 |
| Suicide attempt | 192.40 | 14.97 | 120 | 9303 | 57716 | 56224928 |
| Intentional overdose | 118.18 | 14.97 | 95 | 9328 | 68022 | 56214622 |
| Loss of consciousness | 83.39 | 14.97 | 97 | 9326 | 109252 | 56173392 |
| Coma | 82.42 | 14.97 | 73 | 9350 | 59582 | 56223062 |
| Altered state of consciousness | 77.02 | 14.97 | 48 | 9375 | 22973 | 56259671 |
| Hepatic function abnormal | 72.53 | 14.97 | 54 | 9369 | 34504 | 56248140 |
| Depressed level of consciousness | 56.83 | 14.97 | 58 | 9365 | 56375 | 56226269 |
| Corneal epithelium defect | 47.03 | 14.97 | 11 | 9412 | 327 | 56282317 |
| Anterior chamber cell | 42.30 | 14.97 | 11 | 9412 | 510 | 56282134 |
| Punctate keratitis | 41.38 | 14.97 | 11 | 9412 | 556 | 56282088 |
| Blood creatine phosphokinase increased | 40.16 | 14.97 | 35 | 9388 | 27917 | 56254727 |
| Rheumatoid arthritis | 37.55 | 14.97 | 9 | 9414 | 382595 | 55900049 |
| Somnolence | 34.44 | 14.97 | 81 | 9342 | 163332 | 56119312 |
| Purpura senile | 32.69 | 14.97 | 9 | 9414 | 520 | 56282124 |
| Joint swelling | 32.25 | 14.97 | 5 | 9418 | 289795 | 55992849 |
| Liver disorder | 31.51 | 14.97 | 38 | 9385 | 44332 | 56238312 |
| Corneal oedema | 31.41 | 14.97 | 11 | 9412 | 1411 | 56281233 |
| Neuroleptic malignant syndrome | 31.16 | 14.97 | 21 | 9402 | 11457 | 56271187 |
| Application site injury | 29.36 | 14.97 | 5 | 9418 | 26 | 56282618 |
| Hyponatraemic encephalopathy | 29.17 | 14.97 | 7 | 9416 | 233 | 56282411 |
| Drug intolerance | 28.50 | 14.97 | 5 | 9418 | 264813 | 56017831 |
| Tarsal tunnel syndrome | 27.97 | 14.97 | 8 | 9415 | 531 | 56282113 |
| Bradyphrenia | 27.84 | 14.97 | 16 | 9407 | 6604 | 56276040 |
| Hypokinesia | 26.83 | 14.97 | 20 | 9403 | 12783 | 56269861 |
| Fatigue | 26.60 | 14.97 | 58 | 9365 | 788494 | 55494150 |
| Drug interaction | 26.29 | 14.97 | 86 | 9337 | 209669 | 56072975 |
| Peripheral swelling | 26.22 | 14.97 | 4 | 9419 | 234722 | 56047922 |
| Alcohol interaction | 26.12 | 14.97 | 11 | 9412 | 2322 | 56280322 |
| Blood lactate dehydrogenase increased | 25.96 | 14.97 | 24 | 9399 | 20651 | 56261993 |
| Hypersensitivity | 25.19 | 14.97 | 6 | 9417 | 256402 | 56026242 |
| Labelled drug-drug interaction issue | 24.75 | 14.97 | 8 | 9415 | 803 | 56281841 |
| Delusion | 24.58 | 14.97 | 18 | 9405 | 11197 | 56271447 |
| Vestibular disorder | 24.56 | 14.97 | 9 | 9414 | 1316 | 56281328 |
| Serotonin syndrome | 24.45 | 14.97 | 26 | 9397 | 26464 | 56256180 |
| Dependence | 24.32 | 14.97 | 10 | 9413 | 1987 | 56280657 |
| Postoperative delirium | 23.99 | 14.97 | 5 | 9418 | 86 | 56282558 |
| Bradykinesia | 23.86 | 14.97 | 13 | 9410 | 4841 | 56277803 |
| Drug ineffective | 23.86 | 14.97 | 77 | 9346 | 918912 | 55363732 |
| Application site ulcer | 23.42 | 14.97 | 5 | 9418 | 97 | 56282547 |
| Syncope | 23.17 | 14.97 | 54 | 9369 | 108145 | 56174499 |
| Swelling | 22.80 | 14.97 | 6 | 9417 | 239765 | 56042879 |
| Intentional product misuse | 22.70 | 14.97 | 35 | 9388 | 51469 | 56231175 |
| Blepharospasm | 22.16 | 14.97 | 11 | 9412 | 3387 | 56279257 |
| Delirium | 21.76 | 14.97 | 31 | 9392 | 42486 | 56240158 |
| Resorption bone increased | 21.36 | 14.97 | 8 | 9415 | 1242 | 56281402 |
| Toxicity to various agents | 21.25 | 14.97 | 84 | 9339 | 224480 | 56058164 |
| Blood alkaline phosphatase increased | 20.83 | 14.97 | 29 | 9394 | 38916 | 56243728 |
| Drug dependence | 20.59 | 14.97 | 22 | 9401 | 22511 | 56260133 |
| Intellectual disability | 20.46 | 14.97 | 7 | 9416 | 837 | 56281807 |
| Infusion related reaction | 20.30 | 14.97 | 5 | 9418 | 208926 | 56073718 |
| Rhabdomyolysis | 19.87 | 14.97 | 29 | 9394 | 40629 | 56242015 |
| Aspartate aminotransferase increased | 19.66 | 14.97 | 43 | 9380 | 82559 | 56200085 |
| Hallucination, visual | 19.50 | 14.97 | 19 | 9404 | 17449 | 56265195 |
| Hyperventilation | 19.44 | 14.97 | 12 | 9411 | 5636 | 56277008 |
| Electrocardiogram T wave inversion | 19.40 | 14.97 | 10 | 9413 | 3333 | 56279311 |
| Interstitial lung disease | 18.75 | 14.97 | 34 | 9389 | 57029 | 56225615 |
| Torsade de pointes | 18.72 | 14.97 | 16 | 9407 | 12424 | 56270220 |
| Completed suicide | 18.70 | 14.97 | 57 | 9366 | 133776 | 56148868 |
| Electrocardiogram QT prolonged | 18.54 | 14.97 | 33 | 9390 | 54555 | 56228089 |
| Attention deficit hyperactivity disorder | 18.53 | 14.97 | 9 | 9414 | 2645 | 56279999 |
| Drug eruption | 18.18 | 14.97 | 22 | 9401 | 25741 | 56256903 |
| Agitation | 17.92 | 14.97 | 33 | 9390 | 56003 | 56226641 |
| Product dose omission issue | 17.86 | 14.97 | 6 | 9417 | 204747 | 56077897 |
| Restlessness | 17.62 | 14.97 | 22 | 9401 | 26564 | 56256080 |
| Arthropathy | 17.24 | 14.97 | 6 | 9417 | 200269 | 56082375 |
| Cerebral infarction | 17.17 | 14.97 | 20 | 9403 | 22485 | 56260159 |
| Abnormal behaviour | 17.14 | 14.97 | 19 | 9404 | 20253 | 56262391 |
| Sinusitis | 16.87 | 14.97 | 6 | 9417 | 197575 | 56085069 |
| Arthralgia | 16.77 | 14.97 | 37 | 9386 | 501632 | 55781012 |
| Hypoglycaemic coma | 16.44 | 14.97 | 8 | 9415 | 2359 | 56280285 |
| Pain | 16.17 | 14.97 | 57 | 9366 | 663127 | 55619517 |
| Extrasystoles | 16.02 | 14.97 | 10 | 9413 | 4789 | 56277855 |
| Salivary gland cancer stage IV | 15.90 | 14.97 | 3 | 9420 | 30 | 56282614 |
| Pulse absent | 15.71 | 14.97 | 10 | 9413 | 4957 | 56277687 |
| Alopecia | 15.23 | 14.97 | 16 | 9407 | 293442 | 55989202 |
| Gamma-glutamyltransferase increased | 14.98 | 14.97 | 22 | 9401 | 30983 | 56251661 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sopor | 289.18 | 15.64 | 106 | 7112 | 11446 | 31678680 |
| Drug abuse | 173.52 | 15.64 | 150 | 7068 | 87608 | 31602518 |
| Intentional overdose | 90.28 | 15.64 | 75 | 7143 | 41314 | 31648812 |
| Depressed level of consciousness | 76.08 | 15.64 | 66 | 7152 | 38535 | 31651591 |
| Suicide attempt | 74.04 | 15.64 | 64 | 7154 | 37184 | 31652942 |
| Intentional self-injury | 63.74 | 15.64 | 39 | 7179 | 13276 | 31676850 |
| Blood creatine phosphokinase increased | 61.80 | 15.64 | 61 | 7157 | 41913 | 31648213 |
| Altered state of consciousness | 43.48 | 15.64 | 37 | 7181 | 21014 | 31669112 |
| Overdose | 42.34 | 15.64 | 72 | 7146 | 84592 | 31605534 |
| Neuroleptic malignant syndrome | 41.87 | 15.64 | 33 | 7185 | 16836 | 31673290 |
| Somnolence | 40.09 | 15.64 | 77 | 7141 | 99368 | 31590758 |
| Hepatic function abnormal | 39.82 | 15.64 | 48 | 7170 | 41174 | 31648952 |
| Bradyphrenia | 32.14 | 15.64 | 17 | 7201 | 4387 | 31685739 |
| Eye haematoma | 29.78 | 15.64 | 6 | 7212 | 62 | 31690064 |
| Interstitial lung disease | 29.07 | 15.64 | 51 | 7167 | 61352 | 31628774 |
| Completed suicide | 28.78 | 15.64 | 64 | 7154 | 91450 | 31598676 |
| Drug dependence | 28.10 | 15.64 | 30 | 7188 | 22549 | 31667577 |
| Road traffic accident | 26.32 | 15.64 | 25 | 7193 | 16356 | 31673770 |
| Loss of consciousness | 25.33 | 15.64 | 55 | 7163 | 77300 | 31612826 |
| Gamma-glutamyltransferase increased | 24.60 | 15.64 | 31 | 7187 | 27794 | 31662332 |
| Insomnia | 23.01 | 15.64 | 60 | 7158 | 94776 | 31595350 |
| Liver disorder | 23.00 | 15.64 | 31 | 7187 | 29676 | 31660450 |
| Blood lactate dehydrogenase increased | 21.81 | 15.64 | 25 | 7193 | 20314 | 31669812 |
| Rhabdomyolysis | 20.57 | 15.64 | 45 | 7173 | 63536 | 31626590 |
| Reduced facial expression | 18.36 | 15.64 | 7 | 7211 | 837 | 31689289 |
| Alanine aminotransferase increased | 17.86 | 15.64 | 47 | 7171 | 74609 | 31615517 |
| Delirium | 17.80 | 15.64 | 33 | 7185 | 41388 | 31648738 |
| Decreased appetite | 17.40 | 15.64 | 75 | 7143 | 153142 | 31536984 |
| Hyporesponsive to stimuli | 17.22 | 15.64 | 7 | 7211 | 991 | 31689135 |
| Suicidal ideation | 16.91 | 15.64 | 30 | 7188 | 36376 | 31653750 |
| Disseminated intravascular coagulation | 16.76 | 15.64 | 22 | 7196 | 20515 | 31669611 |
| Off label use | 16.52 | 15.64 | 34 | 7184 | 347240 | 31342886 |
| Amnesia | 15.98 | 15.64 | 23 | 7195 | 23379 | 31666747 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sopor | 848.14 | 14.97 | 297 | 14416 | 30970 | 70882761 |
| Drug abuse | 572.33 | 14.97 | 364 | 14349 | 146892 | 70766839 |
| Intentional self-injury | 259.26 | 14.97 | 128 | 14585 | 31522 | 70882209 |
| Suicide attempt | 258.05 | 14.97 | 176 | 14537 | 79334 | 70834397 |
| Intentional overdose | 198.80 | 14.97 | 164 | 14549 | 98271 | 70815460 |
| Overdose | 188.80 | 14.97 | 203 | 14510 | 169542 | 70744189 |
| Depressed level of consciousness | 119.59 | 14.97 | 117 | 14596 | 87314 | 70826417 |
| Loss of consciousness | 95.08 | 14.97 | 138 | 14575 | 155578 | 70758153 |
| Blood creatine phosphokinase increased | 83.76 | 14.97 | 82 | 14631 | 61181 | 70852550 |
| Hepatic function abnormal | 83.76 | 14.97 | 86 | 14627 | 67910 | 70845821 |
| Altered state of consciousness | 79.24 | 14.97 | 66 | 14647 | 39956 | 70873775 |
| Somnolence | 77.84 | 14.97 | 151 | 14562 | 215455 | 70698276 |
| Coma | 67.41 | 14.97 | 89 | 14624 | 91755 | 70821976 |
| Neuroleptic malignant syndrome | 60.20 | 14.97 | 47 | 14666 | 25960 | 70887771 |
| Corneal epithelium defect | 50.19 | 14.97 | 14 | 14699 | 682 | 70913049 |
| Bradyphrenia | 47.11 | 14.97 | 28 | 14685 | 9918 | 70903813 |
| Anterior chamber cell | 46.56 | 14.97 | 14 | 14699 | 891 | 70912840 |
| Punctate keratitis | 46.33 | 14.97 | 14 | 14699 | 906 | 70912825 |
| Rheumatoid arthritis | 45.77 | 14.97 | 4 | 14709 | 291801 | 70621930 |
| Drug dependence | 43.77 | 14.97 | 46 | 14667 | 37275 | 70876456 |
| Drug ineffective | 38.15 | 14.97 | 87 | 14626 | 939665 | 69974066 |
| Fatigue | 37.93 | 14.97 | 71 | 14642 | 824248 | 70089483 |
| Interstitial lung disease | 37.31 | 14.97 | 73 | 14640 | 104612 | 70809119 |
| Liver disorder | 36.69 | 14.97 | 54 | 14659 | 61514 | 70852217 |
| Joint swelling | 35.84 | 14.97 | 5 | 14708 | 253206 | 70660525 |
| Delirium | 35.49 | 14.97 | 59 | 14654 | 74555 | 70839176 |
| Blood lactate dehydrogenase increased | 35.44 | 14.97 | 40 | 14673 | 35087 | 70878644 |
| Rhabdomyolysis | 34.40 | 14.97 | 67 | 14646 | 95693 | 70818038 |
| Completed suicide | 34.00 | 14.97 | 114 | 14599 | 227021 | 70686710 |
| Corneal oedema | 32.88 | 14.97 | 14 | 14699 | 2446 | 70911285 |
| Hypokinesia | 30.92 | 14.97 | 27 | 14686 | 17405 | 70896326 |
| Gamma-glutamyltransferase increased | 29.54 | 14.97 | 44 | 14669 | 50641 | 70863090 |
| Application site injury | 28.98 | 14.97 | 5 | 14708 | 22 | 70913709 |
| Peripheral swelling | 28.50 | 14.97 | 7 | 14706 | 236556 | 70677175 |
| Hypersensitivity | 27.30 | 14.97 | 7 | 14706 | 229805 | 70683926 |
| Tarsal tunnel syndrome | 26.79 | 14.97 | 8 | 14705 | 497 | 70913234 |
| Purpura senile | 26.70 | 14.97 | 8 | 14705 | 503 | 70913228 |
| Eye haematoma | 26.60 | 14.97 | 6 | 14707 | 121 | 70913610 |
| Hyponatraemic encephalopathy | 25.85 | 14.97 | 7 | 14706 | 305 | 70913426 |
| Drug eruption | 25.51 | 14.97 | 36 | 14677 | 39460 | 70874271 |
| Infusion related reaction | 25.50 | 14.97 | 5 | 14708 | 197529 | 70716202 |
| Off label use | 25.33 | 14.97 | 75 | 14638 | 742985 | 70170746 |
| Drug interaction | 25.24 | 14.97 | 150 | 14563 | 381291 | 70532440 |
| Product dose omission issue | 25.12 | 14.97 | 7 | 14706 | 217461 | 70696270 |
| Drug intolerance | 24.73 | 14.97 | 8 | 14705 | 225679 | 70688052 |
| Decreased appetite | 24.25 | 14.97 | 126 | 14587 | 304654 | 70609077 |
| Aspartate aminotransferase increased | 23.85 | 14.97 | 69 | 14644 | 126909 | 70786822 |
| Hyperventilation | 23.47 | 14.97 | 16 | 14697 | 7170 | 70906561 |
| Miosis | 23.33 | 14.97 | 21 | 14692 | 14080 | 70899651 |
| Delusion | 23.14 | 14.97 | 24 | 14689 | 19141 | 70894590 |
| Heat illness | 23.11 | 14.97 | 7 | 14706 | 457 | 70913274 |
| Abnormal behaviour | 22.95 | 14.97 | 32 | 14681 | 34677 | 70879054 |
| Electrocardiogram QT prolonged | 22.52 | 14.97 | 52 | 14661 | 83465 | 70830266 |
| Confusional state | 22.22 | 14.97 | 117 | 14596 | 284281 | 70629450 |
| Activation syndrome | 21.93 | 14.97 | 6 | 14707 | 272 | 70913459 |
| Cerebral infarction | 21.79 | 14.97 | 35 | 14678 | 42974 | 70870757 |
| Alcohol interaction | 21.78 | 14.97 | 13 | 14700 | 4640 | 70909091 |
| Pain | 21.75 | 14.97 | 63 | 14650 | 628753 | 70284978 |
| Application site ulcer | 21.38 | 14.97 | 5 | 14708 | 119 | 70913612 |
| Alanine aminotransferase increased | 21.14 | 14.97 | 73 | 14640 | 147407 | 70766324 |
| Blood alkaline phosphatase increased | 21.07 | 14.97 | 41 | 14672 | 58480 | 70855251 |
| Labelled drug-drug interaction issue | 21.06 | 14.97 | 8 | 14705 | 1041 | 70912690 |
| Arthralgia | 20.83 | 14.97 | 46 | 14667 | 503344 | 70410387 |
| Lymphocyte stimulation test positive | 20.64 | 14.97 | 8 | 14705 | 1099 | 70912632 |
| Speech disorder | 20.15 | 14.97 | 37 | 14676 | 50543 | 70863188 |
| Swelling | 20.10 | 14.97 | 7 | 14706 | 188532 | 70725199 |
| Treatment failure | 20.03 | 14.97 | 3 | 14710 | 144139 | 70769592 |
| Intentional product misuse | 19.77 | 14.97 | 48 | 14665 | 79547 | 70834184 |
| Insomnia | 19.40 | 14.97 | 93 | 14620 | 217713 | 70696018 |
| Resorption bone increased | 18.90 | 14.97 | 8 | 14705 | 1377 | 70912354 |
| Bradykinesia | 18.32 | 14.97 | 14 | 14699 | 7488 | 70906243 |
| Restlessness | 18.29 | 14.97 | 32 | 14681 | 42096 | 70871635 |
| Postoperative delirium | 18.16 | 14.97 | 5 | 14708 | 232 | 70913499 |
| Vestibular disorder | 17.84 | 14.97 | 9 | 14704 | 2311 | 70911420 |
| Hypoglycaemic coma | 17.39 | 14.97 | 11 | 14702 | 4350 | 70909381 |
| Toxicity to various agents | 17.34 | 14.97 | 137 | 14576 | 382035 | 70531696 |
| Intellectual disability | 17.13 | 14.97 | 7 | 14706 | 1103 | 70912628 |
| Pain in extremity | 17.10 | 14.97 | 26 | 14687 | 328056 | 70585675 |
| Dysarthria | 17.02 | 14.97 | 39 | 14674 | 62274 | 70851457 |
| Arthropathy | 17.01 | 14.97 | 5 | 14708 | 150052 | 70763679 |
| Cough | 16.75 | 14.97 | 26 | 14687 | 325351 | 70588380 |
| Hyporesponsive to stimuli | 16.62 | 14.97 | 8 | 14705 | 1857 | 70911874 |
| Suicidal ideation | 16.26 | 14.97 | 41 | 14672 | 69555 | 70844176 |
| Blepharospasm | 16.09 | 14.97 | 10 | 14703 | 3835 | 70909896 |
| Fall | 15.86 | 14.97 | 151 | 14562 | 443945 | 70469786 |
| Attention deficit hyperactivity disorder | 15.71 | 14.97 | 9 | 14704 | 2978 | 70910753 |
| Alopecia | 15.69 | 14.97 | 11 | 14702 | 198479 | 70715252 |
| Torsade de pointes | 15.56 | 14.97 | 19 | 14694 | 18097 | 70895634 |
| Blood pressure decreased | 15.54 | 14.97 | 48 | 14665 | 91467 | 70822264 |
| Ocular hyperaemia | 15.23 | 14.97 | 22 | 14691 | 24617 | 70889114 |
| Dependence | 15.04 | 14.97 | 8 | 14705 | 2292 | 70911439 |
| Disinhibition | 15.03 | 14.97 | 8 | 14705 | 2293 | 70911438 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CD05 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives |
| FDA CS | M0002356 | Benzodiazepines |
| FDA EPC | N0000175694 | Benzodiazepine |
| MeSH PA | D000759 | Adjuvants, Anesthesia |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018682 | GABA Agents |
| MeSH PA | D018757 | GABA Modulators |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Insomnia | indication | 193462001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Depressive disorder | contraindication | 35489007 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Hypoalbuminemia | contraindication | 119247004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sleep automatism | contraindication | 247962006 | |
| Syncope | contraindication | 271594007 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.22 | Basic |
| pKa2 | 4.62 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| GABA A receptor alpha-5/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.70 | WOMBAT-PK | CHEMBL | |||
| GABA A receptor alpha-3/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.88 | WOMBAT-PK | CHEMBL | |||
| GABA A receptor alpha-3/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.11 | WOMBAT-PK | CHEMBL | |||
| GABA A receptor alpha-5/beta-3/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.70 | WOMBAT-PK | CHEMBL | |||
| GABA A receptor alpha-5/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.22 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.16 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-2/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.23 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-3/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.85 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-5/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.02 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-1/beta-2/gamma-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 8.64 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor alpha-1/beta-3/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.10 | WOMBAT-PK | CHEMBL | |||
| GABA-A receptor | Ion channel | POSITIVE ALLOSTERIC MODULATOR | Ki | 9.10 | IUPHAR | CHEMBL | |||
| Platelet-activating factor receptor | GPCR | Ki | 5.88 | PDSP | |||||
| Cytochrome P450 3A4 | Enzyme | Ki | 4.27 | WOMBAT-PK | |||||
| Cholecystokinin receptor type A | GPCR | IC50 | 4.41 | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | Ki | 9.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018066 | VUID |
| N0000146407 | NUI |
| D00387 | KEGG_DRUG |
| 4018066 | VANDF |
| C0040879 | UMLSCUI |
| CHEMBL646 | ChEMBL_ID |
| DB00897 | DRUGBANK_ID |
| D014229 | MESH_DESCRIPTOR_UI |
| 5556 | PUBCHEM_CID |
| 7313 | IUPHAR_LIGAND_ID |
| 3409 | INN_ID |
| 1HM943223R | UNII |
| 10767 | RXNORM |
| 3103 | MMSL |
| 5618 | MMSL |
| d00397 | MMSL |
| 001466 | NDDF |
| 111128007 | SNOMEDCT_US |
| 386984001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Halcion | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0017 | TABLET | 0.25 mg | ORAL | NDA | 33 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-4858 | TABLET | 0.13 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-4859 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| TRIAZOLAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-236 | TABLET | 0.25 mg | ORAL | NDA authorized generic | 28 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-284 | TABLET | 0.25 mg | ORAL | ANDA | 22 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-303 | TABLET | 0.13 mg | ORAL | ANDA | 22 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-996 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-996 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-996 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-451 | TABLET | 0.25 mg | ORAL | NDA AUTHORIZED GENERIC | 29 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0522 | TABLET | 0.25 mg | ORAL | NDA AUTHORIZED GENERIC | 32 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4733 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50436-3718 | TABLET | 0.25 mg | ORAL | NDA AUTHORIZED GENERIC | 28 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-645 | TABLET | 0.13 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-646 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-787 | TABLET | 0.25 mg | ORAL | NDA authorized generic | 33 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-787 | TABLET | 0.25 mg | ORAL | NDA authorized generic | 33 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59762-3717 | TABLET | 0.13 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59762-3718 | TABLET | 0.25 mg | ORAL | NDA AUTHORIZED GENERIC | 33 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2956 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67544-725 | TABLET | 0.25 mg | ORAL | ANDA | 23 sections |
| Triazolam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-1876 | TABLET | 0.25 mg | ORAL | ANDA | 30 sections |